---
title: 'Regulatory Daily Summary: What Happened on October 11, 2026'
headline: FDA opens expedited trial pilot for cell and gene therapies
description: The agency will choose up to 10 sponsor-institution pairs. Efferon’s
  pediatric sepsis device has a European CE mark.
url: https://thebench.bio/news/regulatory/2026-10-11
topic: regulatory
date: '2026-10-11'
covers:
- '2026-10-11'
date_published: '2026-10-12T00:00:25Z'
date_modified: '2026-10-12T00:00:25Z'
sources: 2
publisher: The Bench (thebench.bio)
---

# Regulatory Daily Summary: What Happened on October 11, 2026

**FDA opens expedited trial pilot for cell and gene therapies**

The agency will choose up to 10 sponsor-institution pairs. Efferon’s pediatric sepsis device has a European CE mark.

## Today in brief

The FDA opened a pilot to speed early cell and gene therapy trials, with applications due October 30. [1] The agency plans to select eight to 10 sponsor-institution pairs by December 18. [1]

Efferon’s pediatric sepsis blood-purification device received a CE mark in April and is used in intensive care units in 30 countries. [2]

## FDA pilot supports early cell and gene therapy trials

Launched September 15 under Operation TrialBlazer, the FDA’s expedited investigational new drug (IND) pilot focuses on cell and gene therapies and retains agency oversight. [1] The pilot offers earlier regulatory discussions and support from qualified research institutions preparing IND submissions. [1]

The FDA has also clarified and reduced some early-stage chemistry, manufacturing, and controls submission requirements. [1] Karim Mikhail said rolling IND submissions could bring earlier FDA feedback. Sharing draft protocols with review boards might shorten trial startup by three to six months, he said. [1]

Applications close October 30, and the FDA plans to select eight to 10 sponsor-institution pairs by December 18. [1] Mikhail said congressional authorization and adequate safeguards would be needed before qualified third parties could approve some low-risk applications. [1]

## Also worth knowing

- Efferon says its CE-marked Efferon NEO can absorb endotoxins and cytokines at the same time, and that it lowers organ-failure rates and speeds recovery in children. The company is preparing an FDA filing. [2]

## The day in numbers

- **8 to 10**: Sponsor-institution pairs the FDA plans to select for the cell and gene therapy pilot by December 18. [1]
- **3 to 6 months**: Potential reduction in trial-startup time from sharing draft protocols with review boards, according to Karim Mikhail. [1]

## Also published

- [Weekly reads:  stem cell and peptides via RFK Jr., Urnov vs. Tie exchange fire, med centers cash in on longevity, the end for Caribou](<https://ipscell.com/2026/10/weekly-reads-stem-cell-and-peptides-via-rfk-jr-urnov-vs-tie-exchange-fire-med-centers-cash-in-on-longevity-the-end-for-caribou/?utm_source=rss&utm_medium=rss&utm_campaign=weekly-reads-stem-cell-and-peptides-via-rfk-jr-urnov-vs-tie-exchange-fire-med-centers-cash-in-on-longevity-the-end-for-caribou>), The Niche

## Sources

1. [Reporter’s Notebook: Cell and Gene Therapy’s Success Lies Beyond the Bespoke (Part 2)](<https://www.insideprecisionmedicine.com/topics/precision-medicine/reporters-notebook-cell-and-gene-therapys-success-lies-beyond-the-bespoke-part-2/>), Inside Precision Medicine, 2026-10-11
2. [Efferon wants to eradicate the devastating toll of pediatric sepsis](<https://techcrunch.com/2026/10/11/efferon-wants-to-eradicate-the-devastating-toll-of-pediatric-sepsis/>), TechCrunch Biotech and Health, 2026-10-11

---

The Bench wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.insideprecisionmedicine.com/topics/precision-medicine/reporters-notebook-cell-and-gene-therapys-success-lies-beyond-the-bespoke-part-2/>
[2]: <https://techcrunch.com/2026/10/11/efferon-wants-to-eradicate-the-devastating-toll-of-pediatric-sepsis/>